2020 ASCO Virtual Direct™ Highlights

 

Hematologic Oncology
20:35

2020 ASCO Virtual Direct™ Highlights

ASCO 2020 CLL Updates: Should Everyone Get Ibrutinib?

FEATURING Manali Kamdar
  • 456 views
  • August 24, 2020
  • 3
12:40

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on DLBCL: What Is the Optimal Venetoclax Dosing w/ EPOCH That Allows Dose Escalation w/o Venetoclax Reduction? Is Auto SCT in R/R DLBCL Pts Achieving Only a PET/CT+ Partial Remission Appropriate in CAR-T Era?

FEATURING Manali Kamdar
  • 121 views
  • August 24, 2020
  • 1
04:47

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Indolent Lymphoma: Obinutuzumab + Chemo vs. Rituximab + Chemo - Is Clinically Meaningful and Durable Benefit With G-Chemo Relative to R-Chemo? How Beneficial Is Axi-Cel?

FEATURING Manali Kamdar
  • 210 views
  • August 24, 2020
  • 2
04:36

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Hodgkin Lymphoma: Is Pembrolizumab a Better Option Than Brentuximab in R/R Hodgkin Patients Post ASCT Or Ineligible for ASCT?

FEATURING Manali Kamdar
  • 27 views
  • August 24, 2020